Phase I trial of daily imatinib mesylate and weekly paclitaxel in patients with advanced refractory solid tumors

被引：0
|
作者：
Bahrani, A [1 ]
Hwang, J [1 ]
Malik, S [1 ]
Marshall, JL [1 ]
机构：
[1] Georgetown Univ Hosp, Washington, DC 20007 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3087
引用
收藏
页码：216S / 216S
页数：1
相关论文
共 50 条
  • [31] Phase I trial of weekly paclitaxel in advanced lung cancer
    Akerley, W
    Glantz, M
    Choy, H
    Rege, V
    Sambandam, S
    Joseph, P
    Yee, L
    Rodrigues, B
    Wingate, P
    Leone, L
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 153 - 158
  • [32] Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors.
    Chatta, GS
    Fakih, M
    Ramalingam, S
    Belani, CP
    Ramanathan, RK
    Zamboni, N
    Friedland, D
    Lis, D
    Tutchko, S
    Egorin, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [33] Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors
    Maurel, J
    Zorrilla, M
    Puertolas, T
    Antón, A
    Herrero, A
    Artal, A
    Alonso, V
    Martinez-Trufero, J
    Puertas, MD
    ANTI-CANCER DRUGS, 2001, 12 (09) : 713 - 717
  • [34] Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
    Messersmith, Wells A.
    Jimeno, Antonio
    Ettinger, David
    Laheru, Dan
    Brahmer, Julie
    Lansey, Dina
    Khan, Yasmin
    Donehower, Ross C.
    Elsayed, Yusri
    Zannikos, Peter
    Hidalgo, Manuel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 181 - 188
  • [35] Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors
    Ready, Neal E.
    Lipton, Alan
    Zhu, Yali
    Statkevich, Paul
    Frank, Emily
    Curtis, Dolores
    Bukowski, Ronald M.
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 576 - 583
  • [36] Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
    Wells A. Messersmith
    Antonio Jimeno
    David Ettinger
    Dan Laheru
    Julie Brahmer
    Dina Lansey
    Yasmin Khan
    Ross C. Donehower
    Yusri Elsayed
    Peter Zannikos
    Manuel Hidalgo
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 181 - 188
  • [37] A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors
    Bekaii-Saab, Tanios S.
    Liu, Jing
    Chan, Kenneth K.
    Balcerzak, Stanley P.
    Ivy, Percy S.
    Grever, Michael R.
    Kraut, Eric H.
    CLINICAL CANCER RESEARCH, 2008, 14 (11) : 3434 - 3440
  • [38] Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
    Mita, Monica
    Mita, Alain
    Sarantopoulos, John
    Takimoto, Chris H.
    Rowinsky, Eric K.
    Romero, Ofelia
    Angiuli, Patrizia
    Allievi, Cecilia
    Eisenfeld, Amy
    Verschraegen, Claire F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) : 287 - 295
  • [39] Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors
    Nakanishi, Y
    Takayama, K
    Wataya, H
    Izumi, M
    Minami, T
    Takano, K
    Inoue, K
    Osaki, S
    Kimotsuki, K
    Harada, T
    Hara, N
    CHEMOTHERAPY, 2002, 48 (04) : 205 - 210
  • [40] Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
    A. Stathis
    D. Hess
    R. von Moos
    K. Homicsko
    G. Griguolo
    M. Joerger
    M. Mark
    C. J. Ackermann
    S. Allegrini
    C. V. Catapano
    A. Xyrafas
    M. Enoiu
    S. Berardi
    P. Gargiulo
    C. Sessa
    Investigational New Drugs, 2017, 35 : 766 - 772
12345